TRAX: SEC Form EFFECT filed by First Tracks Biotherapeutics Inc.
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for TRAX
Across the 17 sessions after earlier TRAX headlines, the stock closed higher 9 times and lower 8 times, with a median move of 4.6% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | TRAX | SPY |
|---|---|---|---|
| Oct 15, 2026 | First Tracks Biotherapeutics Announces $200 Million Private Placement | +5.6% | +0.3% |
| Oct 12, 2026 | First Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac Diseaseand 1 other headline that session | +6.9% | -0.1% |
| Sep 30, 2026 | Canaccord Genuity initiated coverage on First Tracks Biotherapeutics with a new price target | -1.5% | -0.2% |
| Sep 18, 2026 | Evercore ISI initiated coverage on First Tracks Biotherapeutics with a new price target | -1.5% | -0.1% |
| Sep 16, 2026 | Guggenheim initiated coverage on First Tracks Biotherapeutics with a new price target | +1.4% | -0.4% |
| Aug 27, 2026 | First Tracks Biotherapeutics Announces Participation in September Investor Conferences | +1.2% | +0.7% |
Quantisnow market dataNASDAQ
TRAX
First Tracks Biotherapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for TRAX
Full TRAX profile on Quantisnow Follow TRAX and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time